rs137852621
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PM5PP5_Very_Strong
The NM_000023.4(SGCA):c.293G>A(p.Arg98His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000223 in 1,611,678 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R98C) has been classified as Pathogenic.
Frequency
Consequence
NM_000023.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SGCA | NM_000023.4 | c.293G>A | p.Arg98His | missense_variant | 3/10 | ENST00000262018.8 | NP_000014.1 | |
SGCA | NM_001135697.3 | c.293G>A | p.Arg98His | missense_variant | 3/8 | NP_001129169.1 | ||
SGCA | NR_135553.2 | n.329G>A | non_coding_transcript_exon_variant | 3/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SGCA | ENST00000262018.8 | c.293G>A | p.Arg98His | missense_variant | 3/10 | 1 | NM_000023.4 | ENSP00000262018.3 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000203 AC: 5AN: 246232Hom.: 0 AF XY: 0.0000150 AC XY: 2AN XY: 133370
GnomAD4 exome AF: 0.0000206 AC: 30AN: 1459378Hom.: 0 Cov.: 32 AF XY: 0.0000221 AC XY: 16AN XY: 725596
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.0000671 AC XY: 5AN XY: 74474
ClinVar
Submissions by phenotype
Autosomal recessive limb-girdle muscular dystrophy type 2D Pathogenic:9
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 28, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Feb 08, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 98 of the SGCA protein (p.Arg98His). This variant is present in population databases (rs137852621, gnomAD 0.004%). This missense change has been observed in individuals with limb-girdle muscular dystrophy (PMID: 7668821, 8069911, 9192266, 12746421, 22095924, 27120200). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 9435). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SGCA protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SGCA function (PMID: 18535179, 22095924). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 20, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | Mar 01, 2023 | The missense c.293G>A (p.Arg98His) variant in SGCA gene has been reported in homozygous and compound heterozygous states in multiple individuals affected with muscular dystrophy (Fayssoil et al., 2016; Ljunggren et al., 1995). Experimental studies have shown that this missense change affects SGCA function (Gastaldello et al., 2008). This variant is reported with allele frequency of 0.002% in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. This variant has been reported to the ClinVar database as Likely Pathogenic / Pathogenic (multiple submissions). The amino acid change p.Arg98His in SGCA is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Arg at position 98 is changed to a His changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic. In absence of another reportable variant in SGCA gene, the molecular diagnosis is not confirmed. - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Aug 26, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 26, 1994 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 13, 2024 | - - |
Autosomal recessive limb-girdle muscular dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 02, 2022 | Variant summary: SGCA c.293G>A (p.Arg98His) results in a non-conservative amino acid change located in the Dystroglycan-type cadherin-like domain (IPR006644) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 246232 control chromosomes. c.293G>A has been reported in the literature as biallelic genotypes in multiple individuals affected with features of Limb-Girdle Muscular Dystrophy, Autosomal Recessive (example, Eymard_1997, Wu_2018, Pagola-Lorz_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (example, Gastaldello_2008). The most pronounced variant effect results in decreased expression of this alpha-Sarcoglycan mutant in beta-gamma-delta-HEK cells that could be rescued by the proteasomal inhibitor MG132 treatment. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 12, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at